APRI (Aprinoia Therapeutics) NonCurrent Deferred Liabilities: $0.00 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics NonCurrent Deferred Liabilities?

Aprinoia Therapeutics APRI NonCurrent Deferred Liabilities is $0.00 Mil as of Dec. 2023.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Aprinoia Therapeutics's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $0.00 Mil.

Aprinoia Therapeutics NonCurrent Deferred Liabilities Related Terms

Aprinoia Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics NonCurrent Deferred Liabilities Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
0.00 0.00 0.00

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
NonCurrent Deferred Liabilities 0.00 0.00 0.00 0.00 0.00
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Aprinoia Therapeutics (APRI) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Dec. 2023. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' NonCurrent Deferred Liabilities too high?
Aprinoia Therapeutics' current NonCurrent Deferred Liabilities is $0.00 Mil.
How does Aprinoia Therapeutics' NonCurrent Deferred Liabilities compare to ?
Aprinoia Therapeutics' NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.